nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ABCB1—Topotecan—cervical cancer	0.361	0.625	CbGbCtD
Fluoxetine—CYP3A4—Topotecan—cervical cancer	0.216	0.375	CbGbCtD
Fluoxetine—Dyspareunia—Topotecan—cervical cancer	0.0386	0.121	CcSEcCtD
Fluoxetine—Pelvic pain—Topotecan—cervical cancer	0.0116	0.0364	CcSEcCtD
Fluoxetine—Intestinal obstruction—Topotecan—cervical cancer	0.0103	0.0325	CcSEcCtD
Fluoxetine—Neuralgia—Topotecan—cervical cancer	0.0102	0.0319	CcSEcCtD
Fluoxetine—Pleural effusion—Topotecan—cervical cancer	0.00921	0.0289	CcSEcCtD
Fluoxetine—Dysmenorrhoea—Topotecan—cervical cancer	0.00776	0.0244	CcSEcCtD
Fluoxetine—Bone pain—Topotecan—cervical cancer	0.00736	0.0231	CcSEcCtD
Fluoxetine—Respiratory failure—Topotecan—cervical cancer	0.00718	0.0226	CcSEcCtD
Fluoxetine—Pulmonary embolism—Topotecan—cervical cancer	0.00705	0.0222	CcSEcCtD
Fluoxetine—Colitis—Topotecan—cervical cancer	0.00677	0.0213	CcSEcCtD
Fluoxetine—Neuropathy—Topotecan—cervical cancer	0.00662	0.0208	CcSEcCtD
Fluoxetine—Rash maculo-papular—Topotecan—cervical cancer	0.00641	0.0201	CcSEcCtD
Fluoxetine—Neoplasm—Topotecan—cervical cancer	0.00638	0.02	CcSEcCtD
Fluoxetine—Ear pain—Topotecan—cervical cancer	0.006	0.0188	CcSEcCtD
Fluoxetine—Dermatitis bullous—Topotecan—cervical cancer	0.00536	0.0168	CcSEcCtD
Fluoxetine—Anaphylactoid reaction—Topotecan—cervical cancer	0.00529	0.0166	CcSEcCtD
Fluoxetine—Lethargy—Topotecan—cervical cancer	0.00522	0.0164	CcSEcCtD
Fluoxetine—Cardiac arrest—Topotecan—cervical cancer	0.00487	0.0153	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00452	0.0142	CcSEcCtD
Fluoxetine—ORM1—endometrium—cervical cancer	0.00446	0.0426	CbGeAlD
Fluoxetine—Pancytopenia—Topotecan—cervical cancer	0.0042	0.0132	CcSEcCtD
Fluoxetine—SIGMAR1—uterine cervix—cervical cancer	0.00418	0.0399	CbGeAlD
Fluoxetine—Weight increased—Topotecan—cervical cancer	0.00403	0.0126	CcSEcCtD
Fluoxetine—SIGMAR1—decidua—cervical cancer	0.00398	0.038	CbGeAlD
Fluoxetine—Pneumonia—Topotecan—cervical cancer	0.00397	0.0125	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Topotecan—cervical cancer	0.00387	0.0121	CcSEcCtD
Fluoxetine—Stomatitis—Topotecan—cervical cancer	0.00385	0.0121	CcSEcCtD
Fluoxetine—Sweating—Topotecan—cervical cancer	0.00378	0.0119	CcSEcCtD
Fluoxetine—SIGMAR1—endometrium—cervical cancer	0.00378	0.0361	CbGeAlD
Fluoxetine—Epistaxis—Topotecan—cervical cancer	0.00372	0.0117	CcSEcCtD
Fluoxetine—ORM1—female reproductive system—cervical cancer	0.0037	0.0353	CbGeAlD
Fluoxetine—SIGMAR1—mammalian vulva—cervical cancer	0.00366	0.0349	CbGeAlD
Fluoxetine—Haemoglobin—Topotecan—cervical cancer	0.00356	0.0112	CcSEcCtD
Fluoxetine—Rhinitis—Topotecan—cervical cancer	0.00355	0.0112	CcSEcCtD
Fluoxetine—Haemorrhage—Topotecan—cervical cancer	0.00354	0.0111	CcSEcCtD
Fluoxetine—SLC6A2—decidua—cervical cancer	0.00353	0.0337	CbGeAlD
Fluoxetine—Hypoaesthesia—Topotecan—cervical cancer	0.00352	0.0111	CcSEcCtD
Fluoxetine—Pharyngitis—Topotecan—cervical cancer	0.00352	0.011	CcSEcCtD
Fluoxetine—SIGMAR1—uterus—cervical cancer	0.00348	0.0332	CbGeAlD
Fluoxetine—HTR2C—female reproductive system—cervical cancer	0.00332	0.0317	CbGeAlD
Fluoxetine—Chills—Topotecan—cervical cancer	0.00318	0.00998	CcSEcCtD
Fluoxetine—SLC6A4—female reproductive system—cervical cancer	0.00315	0.0301	CbGeAlD
Fluoxetine—Alopecia—Topotecan—cervical cancer	0.00313	0.00983	CcSEcCtD
Fluoxetine—Malnutrition—Topotecan—cervical cancer	0.00308	0.00968	CcSEcCtD
Fluoxetine—Back pain—Topotecan—cervical cancer	0.00298	0.00937	CcSEcCtD
Fluoxetine—Muscle spasms—Topotecan—cervical cancer	0.00296	0.00931	CcSEcCtD
Fluoxetine—Ill-defined disorder—Topotecan—cervical cancer	0.00286	0.00899	CcSEcCtD
Fluoxetine—Anaemia—Topotecan—cervical cancer	0.00285	0.00895	CcSEcCtD
Fluoxetine—SIGMAR1—female gonad—cervical cancer	0.00285	0.0272	CbGeAlD
Fluoxetine—SIGMAR1—vagina—cervical cancer	0.00283	0.027	CbGeAlD
Fluoxetine—Angioedema—Topotecan—cervical cancer	0.00282	0.00885	CcSEcCtD
Fluoxetine—Malaise—Topotecan—cervical cancer	0.00278	0.00873	CcSEcCtD
Fluoxetine—SLC6A2—female reproductive system—cervical cancer	0.00277	0.0265	CbGeAlD
Fluoxetine—Leukopenia—Topotecan—cervical cancer	0.00276	0.00867	CcSEcCtD
Fluoxetine—CYP3A5—uterine cervix—cervical cancer	0.00275	0.0262	CbGeAlD
Fluoxetine—Cough—Topotecan—cervical cancer	0.00269	0.00845	CcSEcCtD
Fluoxetine—CYP1A2—renal system—cervical cancer	0.00266	0.0254	CbGeAlD
Fluoxetine—Chest pain—Topotecan—cervical cancer	0.00262	0.00824	CcSEcCtD
Fluoxetine—Myalgia—Topotecan—cervical cancer	0.00262	0.00824	CcSEcCtD
Fluoxetine—Arthralgia—Topotecan—cervical cancer	0.00262	0.00824	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00261	0.00819	CcSEcCtD
Fluoxetine—Discomfort—Topotecan—cervical cancer	0.00259	0.00815	CcSEcCtD
Fluoxetine—CYP3A5—renal system—cervical cancer	0.00257	0.0245	CbGeAlD
Fluoxetine—CYP2B6—renal system—cervical cancer	0.00255	0.0244	CbGeAlD
Fluoxetine—Anaphylactic shock—Topotecan—cervical cancer	0.00252	0.0079	CcSEcCtD
Fluoxetine—Infection—Topotecan—cervical cancer	0.0025	0.00785	CcSEcCtD
Fluoxetine—Thrombocytopenia—Topotecan—cervical cancer	0.00246	0.00774	CcSEcCtD
Fluoxetine—Skin disorder—Topotecan—cervical cancer	0.00244	0.00768	CcSEcCtD
Fluoxetine—Hyperhidrosis—Topotecan—cervical cancer	0.00243	0.00764	CcSEcCtD
Fluoxetine—Anorexia—Topotecan—cervical cancer	0.0024	0.00753	CcSEcCtD
Fluoxetine—CYP2C19—vagina—cervical cancer	0.00236	0.0225	CbGeAlD
Fluoxetine—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00229	0.0072	CcSEcCtD
Fluoxetine—Paraesthesia—Topotecan—cervical cancer	0.00226	0.0071	CcSEcCtD
Fluoxetine—HTR2A—epithelium—cervical cancer	0.00224	0.0214	CbGeAlD
Fluoxetine—Dyspnoea—Topotecan—cervical cancer	0.00224	0.00705	CcSEcCtD
Fluoxetine—Dyspepsia—Topotecan—cervical cancer	0.00222	0.00696	CcSEcCtD
Fluoxetine—Decreased appetite—Topotecan—cervical cancer	0.00219	0.00687	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Topotecan—cervical cancer	0.00217	0.00682	CcSEcCtD
Fluoxetine—Fatigue—Topotecan—cervical cancer	0.00217	0.00681	CcSEcCtD
Fluoxetine—ORM1—lymph node—cervical cancer	0.00216	0.0207	CbGeAlD
Fluoxetine—Pain—Topotecan—cervical cancer	0.00215	0.00676	CcSEcCtD
Fluoxetine—Constipation—Topotecan—cervical cancer	0.00215	0.00676	CcSEcCtD
Fluoxetine—HTR2A—renal system—cervical cancer	0.00208	0.0199	CbGeAlD
Fluoxetine—Feeling abnormal—Topotecan—cervical cancer	0.00207	0.00651	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Topotecan—cervical cancer	0.00206	0.00646	CcSEcCtD
Fluoxetine—CYP2B6—female reproductive system—cervical cancer	0.00204	0.0195	CbGeAlD
Fluoxetine—CYP2C9—female reproductive system—cervical cancer	0.00202	0.0193	CbGeAlD
Fluoxetine—Urticaria—Topotecan—cervical cancer	0.002	0.00628	CcSEcCtD
Fluoxetine—Abdominal pain—Topotecan—cervical cancer	0.00199	0.00625	CcSEcCtD
Fluoxetine—Body temperature increased—Topotecan—cervical cancer	0.00199	0.00625	CcSEcCtD
Fluoxetine—CYP3A4—renal system—cervical cancer	0.00193	0.0184	CbGeAlD
Fluoxetine—ALB—lymph node—cervical cancer	0.0019	0.0181	CbGeAlD
Fluoxetine—CYP2D6—renal system—cervical cancer	0.0019	0.0181	CbGeAlD
Fluoxetine—CYP3A5—female gonad—cervical cancer	0.00187	0.0179	CbGeAlD
Fluoxetine—CYP3A5—vagina—cervical cancer	0.00186	0.0178	CbGeAlD
Fluoxetine—Hypersensitivity—Topotecan—cervical cancer	0.00185	0.00582	CcSEcCtD
Fluoxetine—CYP2B6—vagina—cervical cancer	0.00185	0.0177	CbGeAlD
Fluoxetine—SIGMAR1—lymph node—cervical cancer	0.00183	0.0175	CbGeAlD
Fluoxetine—Asthenia—Topotecan—cervical cancer	0.00181	0.00567	CcSEcCtD
Fluoxetine—Pruritus—Topotecan—cervical cancer	0.00178	0.00559	CcSEcCtD
Fluoxetine—Diarrhoea—Topotecan—cervical cancer	0.00172	0.00541	CcSEcCtD
Fluoxetine—HTR2A—female reproductive system—cervical cancer	0.00167	0.0159	CbGeAlD
Fluoxetine—Dizziness—Topotecan—cervical cancer	0.00166	0.00523	CcSEcCtD
Fluoxetine—SLC6A2—lymph node—cervical cancer	0.00162	0.0155	CbGeAlD
Fluoxetine—Vomiting—Topotecan—cervical cancer	0.0016	0.00503	CcSEcCtD
Fluoxetine—Rash—Topotecan—cervical cancer	0.00159	0.00498	CcSEcCtD
Fluoxetine—Dermatitis—Topotecan—cervical cancer	0.00159	0.00498	CcSEcCtD
Fluoxetine—Headache—Topotecan—cervical cancer	0.00158	0.00495	CcSEcCtD
Fluoxetine—CYP3A4—female reproductive system—cervical cancer	0.00154	0.0147	CbGeAlD
Fluoxetine—CYP2D6—female reproductive system—cervical cancer	0.00152	0.0145	CbGeAlD
Fluoxetine—HTR2A—vagina—cervical cancer	0.00151	0.0144	CbGeAlD
Fluoxetine—Nausea—Topotecan—cervical cancer	0.00149	0.00469	CcSEcCtD
Fluoxetine—ABCB1—epithelium—cervical cancer	0.00147	0.014	CbGeAlD
Fluoxetine—ABCB1—uterine cervix—cervical cancer	0.00146	0.0139	CbGeAlD
Fluoxetine—ABCB1—decidua—cervical cancer	0.00139	0.0133	CbGeAlD
Fluoxetine—CYP2D6—female gonad—cervical cancer	0.00138	0.0132	CbGeAlD
Fluoxetine—ABCB1—renal system—cervical cancer	0.00136	0.013	CbGeAlD
Fluoxetine—ABCB1—endometrium—cervical cancer	0.00132	0.0126	CbGeAlD
Fluoxetine—ABCB1—mammalian vulva—cervical cancer	0.00128	0.0122	CbGeAlD
Fluoxetine—ABCB1—uterus—cervical cancer	0.00122	0.0116	CbGeAlD
Fluoxetine—ABCB1—female reproductive system—cervical cancer	0.00109	0.0104	CbGeAlD
Fluoxetine—ABCB1—female gonad—cervical cancer	0.000994	0.00949	CbGeAlD
Fluoxetine—ABCB1—vagina—cervical cancer	0.000988	0.00944	CbGeAlD
Fluoxetine—ABCB1—lymph node—cervical cancer	0.000639	0.0061	CbGeAlD
